New York-based Promosome filed separate lawsuits against Moderna and Pfizer, accusing both companies of violating patent protections related to mRNA technology.
In the filings submitted to the Southern District Court of California, Promosome claims that in 2009 company-affiliated scientists “discovered a method for increasing protein expression by making small changes to the mRNA that could affect the amount of protein produced without altering the amino acid sequence encoded by the mRNA.” The technology is based on the discoveries of Promosome CSO Dr. Vincent P. Mauro and the late Nobel Laureate Dr. Gerald M. Edelman of The Scripps Research Institute (TSRI) in La Jolla, California. Leveraging their expertise in the area of mRNA translation resulted in pioneering technologies that Promosome licenses to companies seeking to improve biotherapeutic and bio-industrial protein expression.
COVID Patent Lawsuits
Promosome’s Tuesday filings are the latest in the intellectual property battle over COVID-19 vaccines. n April 2023, Arbutus Biopharma sued Pfizer and BioNTech, alleging that their coronavirus vaccine used proprietary lipid nanoparticle (LNP) technology protected by five patents. The lawsuit claims that the delivery system that Comirnaty uses could not have been produced without Arbutus’ technology.
Alnylam also filed patent infringement lawsuits against Pfizer and Moderna in March 2022, accusing both companies of formulating their vaccines using Alnylam’s proprietary LNP drug delivery technology. Massachusetts Biopharma is seeking “fair compensation” for this infringement.
Moderna and Pfizer are also locked in a legal tussle with each other. In August 2022, Moderna sued Pfizer and BioNTech, claiming that the companies “unlawfully copied Moderna’s inventions, and they have continued to use them without permission,” Shannon Thyme Klinger, chief legal officer of Moderna, said at the time.
Pfizer returned with a countersuit in December 2022, seeking to dismiss Moderna’s lawsuit.
Pfizer, Moderna, and Bionet reaped tremendous profits from research based on the discoveries of Promosome CSO Dr. Vincent P. Mauro and the late Nobel Laureate Dr. Gerald M. Edelman of The Scripps Research Institute (TSRI) in La Jolla, California
This is only the beginning. in a tug of war as others pursue gains from Pfizer-Moderna.
In April 2023, Arbutus Biopharma sued Pfizer and BioNTech, alleging that their coronavirus vaccine used proprietary lipid nanoparticle (LNP) technology protected by five patents. The lawsuit claims that the delivery system that Comirnaty uses could not have been produced without Arbutus’ technology.
No comments:
Post a Comment